Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 4 | 4 | — | — | 2 | 10 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 4 | 4 | — | — | 1 | 9 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | — | 1 |
Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Drug common name | ADOMEGLIVANT |
INN | adomeglivant |
Description | Adomeglivant is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target glucagon receptor. |
Classification | Small molecule |
Drug class | antagonist of the glucagon receptor |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1 |
PDB | — |
CAS-ID | 1488363-78-5 |
RxCUI | — |
ChEMBL ID | CHEMBL3707351 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 74Z5ZL2KVG (ChemIDplus, GSRS) |